BARDA To Support Research Into Ebola Treatment, Vaccine

CQ HealthBeat: Ebola Drug Attracts $38 Million in BARDA Funds, Moves Toward Human Tests
“As much as $38 million in federal funds may be provided under a new agreement for the development of Regeneron Pharmaceuticals Inc.’s Ebola treatment, with an aim of advancing it toward tests in people. … [The Biomedical Advanced Research and Development Authority (BARDA)] on Sept. 14 announced a $28.5 million agreement with Johnson & Johnson for work on an Ebola vaccine…” (Young, 9/21).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.